BiotechTube
Home/Pipeline/Not Specified (Hematologic Malignancies)

Not Specified (Hematologic Malignancies)

Hematologic Malignancies

ClinicalActive

Key Facts

Indication
Hematologic Malignancies
Phase
Clinical
Status
Active
Company
AbelZeta Pharma

About AbelZeta Pharma

AbelZeta Pharma is a clinical-stage biotechnology company pioneering T cell-based therapies for hematologic malignancies, solid tumors, and inflammatory/immunological diseases. The company leverages a proprietary CAR-T platform and is led by a management team with deep experience from major technology and pharmaceutical corporations. While currently a private, pre-revenue entity, it is advancing a pipeline of novel cell therapies with the aim of providing personalized treatments for challenging conditions.

View full company profile

Therapeutic Areas

Hematologic MalignanciesInflammatory & Immunological DiseasesSolid Tumors

Other Hematologic Malignancies Drugs

DrugCompanyPhase
CER-T Cell PlatformCERo TherapeuticsPre-clinical
PredicineHEME™PredicineCommercial
Orca-TBristol Myers SquibbPhase 3
NK‑TheraVectorite BiomedicalPhase 1/2
Trichostatin A (TSA)Vanda PharmaceuticalsDevelopment
DARIC-NK ProgramCoeptis TherapeuticsPreclinical
TSC-102-A01TScan TherapeuticsPreclinical
TSC-102-A03TScan TherapeuticsPreclinical
LBL-007LakeShore BiopharmaPhase 1/2